{
  "id": "5e764440c6a8763d23000013",
  "type": "factoid",
  "question": "How many doses of vaxchora are required?",
  "ideal_answer": "Vaxchora is a single-dose vaccine.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28622736"
  ],
  "snippets": [
    {
      "text": "Vaxchora: A Single-Dose Oral Cholera Vaccine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622736",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "To review trials evaluating the efficacy and safety of Vaxchora, a reformulated, single-dose, oral, lyophilized Vibrio cholerae CVD 103-HgR vaccine for the prevention of travel-related cholera caused by V cholerae serogroup O1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Studies that addressed the safety and efficacy of Vaxchora, the reformulated, single-dose oral CVD 103-HgR cholera vaccine, were selected for analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Approval of Vaxchora, was based on efficacy of the vaccine in human trials demonstrating 90.3% protection among those challenged with V cholerae 10 days after vaccination and in immunogenicity studies with 90% systemic vibriocidal antibody conversion at 6 months after a single-dose of vaccine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Vaxchora is the only FDA-approved, single-dose oral vaccine for the prevention of cholera caused by V cholerae serogroup O1 in adult travelers from the United States going to cholera-affected areas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622736",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "one"
}